GLP-1 receptor agonists slow biological aging or extend healthspan in humans.
- Current status
- Mechanistic onlyEvidence stable · Aging
- Why
- Reviews describe mitochondrial, senescence and vascular-aging mechanisms and cite aged-mouse multi-omic data. No human trial has a prespecified aging endpoint; no epigenetic-clock or healthspan outcome trial exists. Mortality reductions in CVOTs occurred in high-risk diabetic or cardiovascular populations.
- What would change it
- A randomized trial in older adults without obesity with validated aging biomarkers AND functional outcomes.
Consistent all-cause mortality reduction in a low-risk population. - Linked studies
- 3 · 2 mechanism only · 1 doesn't directly test the claim
- Last updated
- Sep 13, 2026
The status is the collection's own judgment on its assessment scale, not a GRADE certainty rating and not medical advice.
01The evidence
The evidence, sorted by what it shows
Mechanism only (2)
- The GLP-1-Mitochondria Axis in Metabolic AgingMechanistic review · 2026 · Not rated · Not human evidence · Unclear
Aging Cell review: no trial with mitochondrial endpoint; human mechanistic evidence limited.
- Prevention of Vascular Aging as a Novel Paradigm for GLP-1 Receptor Agonist-Mediated CardioprotectionMechanistic review · 2026 · Not rated · Not human evidence · Unclear
Circ Res review: vascular-aging hypothesis.
Doesn't directly test the claim (1)
- Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trialsMeta-analysis · 2021 · Study tier 1 · Different population · Benefit
All-cause mortality HR 0.88 in T2D CVOTs; high-risk populations only.
02History
How this assessment has changed
- Mechanistic onlySep 13, 2026 · Evidence stable
initial curated status